Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arthur J. Provisor is active.

Publication


Featured researches published by Arthur J. Provisor.


The American Journal of Medicine | 1982

Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): Update on studies of the registry

David T. Purtilo; Kiyoshi Sakamoto; Vanessa M. Barnabei; J K Seeley; Thomas Bechtold; Geraldine Rogers; Joanne Yetz; Shinji Harada; Izet Berkel; Carter D. Brooks; George Bucchanan; Robert D. Collins; Frank G. Cruzi; Gerald Z. Finkelstein; Anders Glomstein; John Greally; Margaret Grunet; Gertrude Henle; Werner Henle; Elvin Kaplan; George Klein; Martin R. Klemperer; Benjamin H. Landing; Sevre Lie; Robert Maier; Helen S. Maurer; Michael Medici; Hans D. Ochs; Lauren M. Pachman; Paul K. Pattengale

Analyses of 100 subjects with the X-linked lymphoproliferative syndrome (XLP) in 25 kindreds revealed four major interrelated phenotypes: infectious mononucleosis, malignant B-cell lymphoma, aplastic anemia, and hypogammaglobulinemia. Eighty-one of the patients died. Two male subjects were asymptomatic but showed immunodeficiency to Epstein-Barr virus (EBV). Seventy-five subjects had the infectious mononucleosis phenotype and concurrently, 17 subjects of this group had aplastic anemia. All subjects with aplastic anemia died within a week. Aplastic anemia did not accompany hypogammaglobulinemia or malignant lymphoma phenotypes. Hypogammaglobulinemia had been detected before infectious mononucleosis in three subjects, after infectious mononucleosis in five subjects, and was not associated with infectious mononucleosis in 11 boys with hypogammaglobulinemia. In nine subjects infectious mononucleosis appeared to have evolved into malignant lymphoma; however, the majority of patients with malignant lymphoma showed no obvious antecedent infectious mononucleosis. One subject had infectious mononucleosis following recurrent malignant lymphoma. Twenty-six of 35 lymphomas were in the terminal ileum. Results of immunologic and virologic studies of 15 survivors revealed combined variable immunodeficiency and deficient antibody responses to EBV-specific antigens. Mothers of boys with XLP exhibited abnormally elevated titers of antibodies of EBV. Subjects of both sexes with phenotypes of XLP should be investigated for immunodeficiency to EBV. Persons with inherited or acquired immunodeficiency may be vulnerable to life-threatening EBV-induced diseases.


Cancer | 1983

Effect of nutrition staging on treatment delays and outcome in stage IV neuroblastoma

Karyl A. Rickard; Catherine M. Detamore; Thomas D. Coates; Jay L. Grosfeld; Robert M. Weetman; Nancy Matchett White; Arthur J. Provisor; Laurence A. Boxer; Emily Loghmani; Tjien O. Oei; Pao‐lo ‐l Yu; Robert L. Baehner

The effect of the state of nutrition of 18 children with Stage IV neuroblastoma at diagnosis and during initial therapy, was evaluated with respect to treatment delays, drug dosage alterations, tumor response, days to first event (relapse or death), and survival. All patients received similar therapy (CCSG protocol CCG 371). Based on nutrition staging at diagnosis, nine were classified as malnourished; four were randomized to receive total parenteral nutrition (TPN) and four peripheral parenteral nutrition plus enteral nutrition for 28 days (through 2 chemotherapy courses), and one died before randomization. Nine were nourished at diagnosis; seven received a comprehensive enteral nutrition program and two received TPN. By life‐table analysis, the duration of remission was significantly greater in the nourished than the malnourished (P < 0.01) and a trend towards improved survival was evident at one year (P = 0.08). The median length of survival for children nourished at diagnosis was approximately 12 months, whereas those malnourished had a median survival of only 5 months. Nine children remained nourished or were becoming renourished during the first 21 days of therapy, and one of these had treatment delays and decreased drug dosages. Seven were becoming malnourished or remained malnourished during this period and six had treatment delays (P < 0.01). These data support the idea that nutrition staging at diagnosis and during initial treatment should be an integral part of protocol design and initial evaluation of children with Stage IV neuroblastoma.


Transplantation | 1986

Radiation nephritis following total-body irradiation and cyclophosphamide in preparation for bone marrow transplantation

Jerry M. Bergstein; Sharon P. Andreoli; Arthur J. Provisor; Moonahm Yum

Two children prepared for bone marrow transplantation with total-body irradiation and cyclophosphamide developed hypertension, microscopic hematuria, proteinuria, diminished renal function, and anemia six months after transplantation. Light microscopy of the kidneys revealed mesangial expansion, glomerular capillary wall thickening, and lumenal thrombosis. Electron microscopy demonstrated widening of the subendothelial space due to the deposition of amorphous fluffy material. In one patient, immunofluorescence microscopy revealed glomerular capillary wall deposition of fibrin and immunoglobulins. The clinical and histologic findings support the diagnosis of radiation nephritis. Patients prepared for bone marrow transplantation with total-body irradiation and cyclophosphamide should be followed closely after transplantation for the development of hypertension, proteinuria, and renal insufficiency.


The Journal of Pediatrics | 1980

X-Linked Lymphoproliferative Syndrome Registry report

Janet K. Hamilton; Louise A. Paquin; John L. Sullivan; Helen S. Maurer; Frank G. Cruzi; Arthur J. Provisor; C. Philip Steuber; Edith P. Hawkins; David H. Yawn; Jo Ann Cornet; Kathryn Clausen; Gerald Z. Finkelstein; Benjamin H. Landing; Margaret L. Grunnet; David T. Purtilo

Immune deficiency, especially to the Epstein-Barr virus, and increased susceptibility to fatal infectious mononucleosis, acquired agammoglobulinemia, and lymphoma are the cardinal features of the X-linked lymphoproliferative syndrome. Since the establishment of the XLP Registry in September, 1978, 59 affected males in seven unrelated kindreds were comprehensively studied. A spectrum of lymphoproliferative phenotypes was observed. Thirty-four patients (57%) died from infectious mononucleosis, eight (14%) had fatal infectious mononucleosis with lymphoma (immunoblastic sarcoma), nine (15%) had depressed immunity following EBV infection, and eight (14%) developed lymphoma. Several patients with XLP lacked EBV antibodies despite infection by EBV. The results of this study suggest that EBV can be an oncogenic agent in patients who are immune deficient with XLP.


Cancer | 1998

Epidemiology of osteosarcoma and Ewing's sarcoma in childhood

Jonathan D. Buckley; Thomas W. Pendergrass; Constance M. Buckley; Douglas J. Pritchard; Mark E. Nesbit; Arthur J. Provisor; Leslie L. Robison

The Childrens Cancer Group conducted a case‐control study to determine the role of a broad range of environmental and familial factors in the etiology of Ewings sarcoma and osteosarcoma in children. These factors included radiation exposure and, for children with osteosarcoma, parental exposure to beryllium.


British Journal of Haematology | 1985

Leukaemic transformation of engrafted bone marrow cells.

Janice L. Smith; Nyla A. Heerema; Arthur J. Provisor

Recurrent leukaemia following bone marrow transplantation is most often due to the regrowth of original host leukaemia cells, but may also be due to the malignant transformation of normal donor marrow cells after transplantation into a leukaemia patient. We report the ninth case of malignant change in cells of donor origin in a 12‐year‐old boy who was originally diagnosed as having Ph1+ CML. He remained Ph1+ during lymphoid blast crisis. After transplantation with marrow from a cytogenetically normal sister, he relapsed to Ph1– ALL in the female donor cells. The marrow showed a mixed karyotype of 46,XX/46,XX,inv(9)(p12q12). It would appear that, haematologically, the patient showed different manifestations of the same disease state. Cytogenetically, however, the pre‐ and post‐transplant leukaemias were different.


Cancer | 1985

Short- and long-term effectiveness of enteral and parenteral nutrition in reversing or preventing protein-energy malnutrition in advanced neuroblastoma a prospective randomized study

Karyl A. Rickard; Emily Loghmani; Jay L. Grosfeld; Catherine Detamore Lingard; Nancy Matchett White; Beth Bartlett Foland; Barbara L. Jaeger; Thomas D. Coates; Pao-Lo Yu; Robert M. Weetman; Arthur J. Provisor; Tjien O. Oei; Robert L. Baehner

The effectiveness of enteral and parenteral nutrition regimens in preventing or reversing protein–energy malnutrition (PEM) and in preventing treatment delays was evaluated in 32 children receiving treatment for newly diagnosed Stage III (3 patients) and IV (29 patients) neuroblastoma. Ten of 18 malnourished patients were randomized to central parenteral nutrition (CPN) and 8 to peripheral parenteral nutrition (PPN) plus enteral nutrition for 4 weeks and then received enteral nutrition (EN: intense nutrition counselling, oral foods and supplements) for weeks 5 through 10. Ten of 14 nourished patients received EN and 4 CPN for 4 weeks and EN thereafter. Dietary, anthropometric and biochemical measurements were determined for weeks 0, 1, 2, 3, 4, 7, and 10 for 24 patients who completed the protocols. In malnourished patients, both CPN (seven patients) and PPN (seven patients) were effective in reversing PEM in the first 4 weeks; thereafter, EN effectively maintained nutritional gains in both groups. In nourished patients, EN (seven patients) was not as effective as CPN (three patients) in preventing PEM during the first 4 weeks; afterwards, EN maintained gains in the CPN group but did not promote needed increases in weight nor fat reserves in the EN group. Patients supported by parenteral nutrition (PN, weeks 1–4) had fewer treatment delays (2/17, 12%) than EN patients (4/7, 57%, P <0.05). These data indicate that PN reverses or prevents PEM and prevents treatment delays during the first 4 weeks of intense oncologic treatment and provides nutritional benefits which can be maintained with EN thereafter.


The Journal of Pediatrics | 1983

Invasive aspergillosis of paranasal tissues in children with malignancies.

Roger L. Berkow; Steven J. Weisman; Arthur J. Provisor; Robert M. Weetman; Robert L. Baehner

Paranasal aspergillosis was encountered in five children with relapsed malignancies. All had received broad-spectrum antibiotics within two weeks of development of aspergillosis, and all had absolute granulocyte counts less than 200/mm3 for at least three weeks. None had received prior antifungal therapy. There was an average delay of eight days before the correct diagnosis was established by either biopsy or culture. These data emphasize the need to obtain surveillance cultures of the upper respiratory tract passages in severely neutropenic patients receiving prolonged antibiotic therapy, and raise a question concerning prophylactic use of antifungal therapy in this group.


Pediatric Radiology | 1985

Magnetic resonance imaging of lymphomas in children

Mervyn D. Cohen; E. C. Klatte; John A. Smith; P. Martin-Simmerman; B. Carr; Robert L. Baehner; Robert M. Weetman; Arthur J. Provisor; T. Coates; R. Berkow; Steven J. Weisman; S. McKenna; W. McGuire

Magnetic resonance imaging has been used to evaluate 10 children with lymphomas and was able to identify disease in all 10 cases and monitor response to therapy in all three patients with follow-up studies. It could not distinguish between the different histological types of lymphoma. The image intensity of a diseased spleen in one case was different from that of five other normal spleens in six children with Hodgkins disease. Magnetic resonance imaging compared well with computed tomography and it was especially good at identifying blood vessels.


Blood | 2003

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

Bruce Bostrom; Martha R. Sensel; Harland N. Sather; Paul S. Gaynon; Mei K. La; Katherine Johnston; Gary R. Erdmann; Stuart Gold; Nyla A. Heerema; Raymond J. Hutchinson; Arthur J. Provisor; Michael E. Trigg

Collaboration


Dive into the Arthur J. Provisor's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Benjamin H. Landing

Children's Hospital Los Angeles

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge